ArticleCureus2026
Iatrogenic Dextrose Hyperosmolar Extravasation Injury in Suspected Endogenous Hyperinsulinism.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyperosmolar dextrose infused through peripheral venous access can extravasate into surrounding soft tissue and produce local injury. We present the case of a 44-year-old woman with a history of seizure disorder and hyperlipidemia who underwent anterior lumbar interbody fusion (ALIF). On the day of admission, she experienced a witnessed generalized seizure on the floor that terminated following administration of intravenous lorazepam. Point-of-care glucose obtained during the event was 39 mg/dL and corrected with intravenous dextrose. She was transferred to the intensive care unit (ICU), where hypoglycemia recurred despite continuous dextrose support. Computed tomography (CT) of the head showed no acute intracranial process, and electroencephalography (EEG) demonstrated diffuse slowing without epileptiform activity. Endocrinology was consulted, and the clinical picture was felt to be most consistent with endogenous hyperinsulinism from a suspected insulinoma. At a serum glucose of 55 mg/dL, insulin was 13 uIU/mL and C-peptide was 4.7 ng/mL, both inappropriately unsuppressed and consistent with endogenous hyperinsulinism. She was maintained on continuous 10% dextrose at 150-200 mL per hour with as-needed 50% dextrose boluses, glucagon, and subcutaneous octreotide 200 mcg every eight hours, with capillary glucose monitoring every two hours. On hospital day 4, the peripheral catheter site was found to be infiltrated, and the catheter was removed, with the infusion transferred to central access. On hospital day 6, nursing and physician staff identified multiple tense, fluid-filled bullae over the right anterior forearm with associated swelling and erythema at the site of a previously removed peripheral intravenous catheter. The patient reported that forearm tenderness had been present since admission and had progressively worsened. Examination demonstrated moderate asymmetric swelling of the right upper extremity with intact distal pulses and preserved sensation. Range of motion was limited by swelling and a sensation of heaviness rather than by pain. The findings were felt to be most consistent with hyperosmolar dextrose extravasation injury. This case demonstrates that sustained peripheral administration of concentrated dextrose can produce progressive bullous and soft tissue injury and that these changes may evolve insidiously over several days. Early changes may be subtle and difficult to distinguish from routine infusion site irritation. Patients with suspected endogenous hyperinsulinism often require a multiday dextrose bridge while localization and definitive treatment are arranged, which places them at particular risk. Early consideration of central venous access, structured infusion site surveillance, and prompt escalation when local changes are identified are important components of care in patients requiring prolonged high-concentration dextrose therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.